Admin Core

管理核心

• 批准号: 10269640
• 负责人: Jean-Pierre J. Issa
• 金额: $ 38.72万
• 依托单位: CORIELL INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10269640
• 关键词: Address; Administrator; Advocate; Award; Cancer Prognosis; Clinic; Clinical; Clinical Trials; Collaborations; Communication; Complex; Consultations; Data; Decision Making; Development; Electronic Mail; Eligibility Determination; Ensure; Genomics; Government; Grant; Infrastructure; Institutes; Interdisciplinary Study; Laboratories; Leadership; Malignant Neoplasms; Medical Research; Minority; Monitor; National Cancer Institute; Outcome; Pathology; Patients; Policies; Preparation; Progress Reports; Protocols documentation; Publications; Quality Control; Regulation; Reporting; Research; Research Activity; Research Infrastructure; Research Personnel; Research Project Grants; Resource Sharing; Strategic Planning; Supervision; Therapeutic Studies; Time; Translational Research; United States National Institutes of Health; Woman; Work; base; cancer care; cancer therapy; career; clinical research site; data sharing; design; epigenetic therapy; experience; improved; interdisciplinary collaboration; lectures; meetings; novel; novel therapeutic intervention; programs; quality assurance; recruit; screening; success; symposium; web site

PROJECT SUMMARY The Administrative Core will provide essential support to the Coriell Institute for Medical Research (Coriell) and Van Andel Institute (VAI) Epigenetic Therapy SPORE PIs and investigators to maximize success. It will be co- directed by Drs. Jean-Pierre Issa, Stephen Baylin, and Peter Jones, who co-chair the Executive Committee and provide overall supervision of three Projects, two additional Cores, Developmental Research (DRP) and Career Enhancement (CEP) Programs, and scientific direction of the SPORE. The Core Co-Directors will rely on the extensive broad-based scientific, research, and SPORE experience of the Internal and External Advisory Boards in critical decision making. An oversight committee consisting of the SPORE PIs and three clinical experts from the VAI-SU2C team (Drs. Rudin, El-Khoueiry and O’Connell) will ensure prioritization of SPORE trials within the VAI-SU2C team and at clinical sites. Success of the complex interdisciplinary research in the SPORE depends on integration of diverse epigenetic therapy research approaches. The Core will overcome barriers to interdisciplinary collaboration and data sharing and will ensure a unified translational research effort. The SPORE will be founded on planning, integration, and translational research efforts supported by this Core. Its leadership and staff will be responsible for monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational research; ensuring interdisciplinary and inter-SPORE integration with major epigenetic therapy programs within/outside Coriell and VAI and other broad translational research activities; and providing optimal administrative and fiscal management. Specific responsibilities of the Core are: oversee and monitor all SPORE activities; promote integration and communication among the SPORE-related clinical programs; monitor the scientific integrity of all projects, and grant awards; assure compliance with institutional, governmental, and National Cancer Institute regulations; oversee the fiscal and budgetary activities of the SPORE; coordinate data control quality assurance issues; coordinate activities associated with clinical trials, including design of protocols, approval by regulatory bodies, implementation, and eligibility screening and assignment of patients to different studies; provide oversight and support for the shared Resources Cores; coordinate and manage meetings of the SPORE Oversight Committee, Executive Committee, Internal and External Advisory Boards, investigator meetings, research meetings, lectures, and symposia; administer the DRP and the CEP; coordinate interdisciplinary and inter-SPORE interactions and exchanges/meetings with other Epigenetic Therapy SPORE programs and investigators, and other SPORE programs; administer the activities of the Patient Advocates; comply with, and improve policies addressing recruitment and retention of women and minorities; and maintain a Epigenetic Therapy SPORE website focused on issues in epigenetic therapy translational research in cancers.

项目总结 行政核心将向科里尔医学研究所(科里尔)和 范安德尔研究所(VAI)表观遗传疗法孢子PI和研究人员，以最大限度地成功。它将是共同的- 由Jean-Pierre Issa、Stephen Baylin和Peter Jones博士执导，他们是执行委员会和 提供对三个项目、两个额外核心、发展研究(DRP)和职业生涯的全面监督 加强(CEP)计划，以及孢子的科学指导。核心联席董事将依靠 内部和外部咨询委员会具有广泛的科学、研究和孢子经验 在关键的决策中。监督委员会由孢子PI和来自 VAI-SU2C团队(Rudin、El-Khoueary和O‘Connell博士)将确保在 VAI-SU2C团队和临床现场。孢子中复杂的跨学科研究的成功取决于 论多种表观遗传疗法研究方法的整合。核心将克服障碍，以 这将有助于实现跨学科协作和数据共享，并将确保统一的翻译研究工作。孢子 将建立在该核心支持的规划、整合和翻译研究工作的基础上。它的领导层 工作人员将负责监测/规划科学活动；提供科学指导；确保 重视翻译研究；确保与主要表观遗传学的跨学科和跨孢子整合 Coriell和VAI内外的治疗计划以及其他广泛的转化性研究活动；以及提供 优化行政和财政管理。核心的具体职责是：监督和监督所有 孢子活动；促进与孢子相关的临床项目之间的整合和交流；监测 所有项目的科学完整性，并授予奖项；确保符合机构、政府和 国家癌症研究所条例；监督孢子的财政和预算活动；协调数据 控制质量保证问题；协调与临床试验相关的活动，包括设计方案； 监管机构的批准、实施和资格筛选以及将患者分配到不同的 研究；为共享资源核心提供监督和支助；协调和管理 孢子监督委员会、执行委员会、内部和外部咨询委员会、调查员 会议、研究会议、讲座和座谈会；管理DRP和CEP；协调 与其他表观遗传疗法孢子的跨学科和跨孢子互动及交流/会议 项目和调查人员，以及其他孢子项目；管理患者权益倡导者的活动； 遵守并改进关于招聘和留住妇女和少数群体的政策； 一个表观遗传疗法孢子网站，专注于表观遗传疗法在癌症翻译研究中的问题。